Product/Service

Endocrinology

Source: QuintilesIMS
We can be your partner to mitigate the effects of longer timelines, additional costs, and higher risk in your clinical development program.

We can be your partner to mitigate the effects of longer timelines, additional costs, and higher risk in your clinical development program. Coupling our deep experience with therapeutic expertise across our commercial, consulting and capital groups, our focus goes beyond the clinical trial to ensure your product gains market access and reaches physicians and patients worldwide.

Since 2000, our endocrinology team has conducted more than 350 trials, enrolling more than 225,000 patients with conditions including:

  • Diabetes
  • Obesity
  • Calcium disorders (Osteoporosis)
  • Growth hormone disorders (including acromegaly)
  • Pituitary hormone disorders (including hyperprolactinemia and hyperthyroidism)

Our medical and clinical experts understand the clinical development challenges in these areas and can work with you to ensure your plan is strategic, efficient, and effective.

Experts in diabetes clinical development in a new regulatory environment
New regulatory guidance has altered the clinical development landscape for anti-diabetic therapies. Length and trial requirements have extended, increasing the cost of development and complexity of data requirements. It is critical, now more than ever, to have an ally who understands the implications throughout the product lifecycle to:

  • Ensure trial development meets global regulations.
  • Track cardiovascular events.
  • Assess long-term risk.
  • Increasing market access.
  • Implement targeted messaging and tools to ensure patient compliance.
  • Develop partnerships to manage risks and costs.